The global hearing device industry is currently benefitting from an ageing population. But what is going to drive growth when the demographic trend is reversed? MedWatch spoke to the Danish industry majors about the issue.
Sweden-based health tech and rehab group Handicare has elected Ambu’s CEO, Lars Marcher, as chairman of its board of directors. It brings another Danisn touch to the company whose majority shareholder is a fund managed by a Danish investor.
Former Novo Nordisk CEO Lars Rebien Sørensen would like to see a list of objective criteria for where EMA will be placed after Brexit and warns about what might happen if the agency ends up the wrong place.
A national genome center will open in the Danish capital Copenhagen and reinforce efforts to develop personalized medicine. The Danish pharma association says the center lacks focus on one crucial element.
The head of Novo Nordisk’s North American business, Jakob Riis, has made the necessary changes to facilitate a turnaround in his first five months in the job. He now has the freedom and room to maneuver that should lead to twice as big a share of the market for the group's major insulin hope.
The Danish government has now officially announced its intention to bring the European Medicines Agency to Denmark and has made former Novo Nordisk CEO Lars Rebien Sørensen its “special envoy”. He will compete with a top diplomat from Sweden, among others.
All hopes seem to be lost for Lundbeck with Alzheimer’s candidate idalopirdine, as the last two phase III studies have been as disappointing as the first and the group has decided not to pursue a regulatory path for the drug.
The next head of Novo Nordisk’s European business is likely to come from outside the company ranks, but CEO Lars Fruergaard is in no rush to find the executive to take up his old position. Increased uncertainty in the US means the group is preparing for a dip in sales for the first time in decades.
Sales of the Genmab-developed cancer drug Darzalex have been so strong throughout 2016 that the biotech is raising its financial guidance for 2016 just a few weeks before the publication of the annual report.
The head of Novo Nordisk’s R&D work admits the company has reached a certain level of maturity in its own research in Denmark and is now “highly dependent” on external basic research. That is the reason for a new GBP 115 investment in the University of Oxford.
Medical device company Coloplast is about to close the chapter on the plethora of lawsuits the company has been met with since 2013 due to its faulty transvaginal mesh products. 95 percent of the cases have been settled, the company said in its interim report.
Novo Nordisk has been met with a number of lawsuits this month, the latest announced this week. But although it happens at a bad time for the hard-tried company, it will not have a material impact on its business, according to one analyst.
Novo Nordisk is establishing a new research center at the University of Oxford and has struck a deal with the university for the discovery of innovative approaches for treating type 2 diabetes. The company is dedicating 100 scientists and GBP 115 million to the project.
Roche's Chairman is a big fan of the Danish life science industry, the talent of which is among the chief reasons why the company is investing in Denmark. But he also cautions the country’s politicians.
Copenhagen and Malmö, the main constituents of the so-called Medicon Valley, will house Europe’s biggest biotech conference, BIO-Europe, in 2018. It could pave the way for increased export and investment in the region, says Novo Nordisk.
Genmab’s bone marrow cancer treatment has delivered the goods with fresh data presented at a hematology conference in San Diego. It reinforces the drug’s position in the market and the entire future foundation for the Danish biotech company, says an analyst.
Although Novo Nordisk has discontinued its activities in what CSO Mads Krogsgaard Thomsen has previously called the Holy Grail of diabetes care, he is not resigned to letting go completely. A partnership with the world’s most cited researcher could bring Novo back in the game. But for now, he has turned his attention to another Holy Grail.